# A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

> **NCT07290062** · PHASE1 · RECRUITING · sponsor: **Insmed Gene Therapy LLC** · enrollment: 23 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **GENETIC:** INS1202

## Key facts

- **NCT ID:** NCT07290062
- **Lead sponsor:** Insmed Gene Therapy LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290062, "A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07290062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*